Suven Life Sciences (SUVEN) | Stock Overview & Key Data
Suven Life Sciences Performance Comparison
Stock Range
Today's Range
Low: ₹250.80
High: ₹263.90
on August 8, 2025
52 Week Range
Low: ₹102.50
High: ₹299.99
on February 28, 2025
on July 15, 2025
All-Time High: ₹338.50 on April 13, 2015
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR61.0B
EPS
-7.42
P/E Ratio (TTM)
-34.61
Forward P/E
13.85
P/B Ratio
53.14
PEG Ratio
13.85
Div. Yield
N/A
ROE
-84.60%
Beta
0.914
Debt to Equity
0.00
Financial Highlights
Profitability
Gross Margin
100.00%
Operating Margin
-3,051.38%
Profit Margin
100.00%
Returns and Earnings
Return on Assets (TTM)
-50.94%
Return on Equity (TTM)
-84.60%
EBITDA
INR-1.7B
Net Income (TTM)
INR-1.6B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR0.31
Quarterly Revenue Growth (YoY)
-38.50%
Quarterly Earnings Growth (YoY)
-38.50%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Suven Life Sciences SUVEN | 60.97B Mid-cap | -6.00% | -7.40% | 81.96% | 93.19% | 96.06% | 90.95% | 259.31% | 395.16% |
| Sun Pharmaceutical SUNPHARMA | 3.92T Large-cap | -2.63% | -5.12% | -10.20% | -8.38% | -16.03% | -8.55% | 73.73% | 198.65% |
| Divi's Laboratories DIVISLAB | 1.63T Large-cap | -7.03% | -14.75% | -0.77% | -0.41% | -2.61% | 22.45% | 58.73% | 91.42% |
| Alembic APLLTD | 184.02B Mid-cap | -2.38% | -6.43% | 3.77% | 5.42% | -10.75% | -15.92% | 45.65% | -8.45% |
| Jubilant Pharmova JUBLPHARMA | 174.95B Mid-cap | -5.02% | -5.59% | 24.87% | 10.08% | 1.88% | 27.78% | 214.12% | 81.50% |
| Natco Pharma NATCOPHARM | 165.30B Mid-cap | -2.50% | -7.83% | 13.12% | -29.19% | -35.03% | -36.97% | 40.23% | 9.43% |
Ownership & Short Interest
Insider Ownership
67.50%
Institutional Ownership
3.88%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
101K
Average 90-Day Volume
176K
Suven Life Sciences Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Suven Life Sciences would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is SUVEN's 52-week high and low?
- In the last 52 weeks, Suven Life Sciences reached a high of ₹299.99 (on July 15, 2025) and a low of ₹102.50 (on February 28, 2025).
- What is the market cap and P/E ratio for SUVEN?
- Curious about Suven Life Sciences's size and valuation? Its market capitalization stands at 60.97B. When it comes to valuation, the P/E ratio (trailing twelve months) is -34.61, and the forward P/E (looking ahead) is 13.85.
- Does SUVEN pay dividends? If so, what's the yield?
- As for dividends, Suven Life Sciences isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Suven Life Sciences's main competitors or similar companies to consider before investing?
When looking at Suven Life Sciences, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.92T Healthcare Drug Manufacturers - Specialty & Generic -8.55% 73.73% Divi's Laboratories
DIVISLAB1.63T Healthcare Drug Manufacturers - Specialty & Generic 22.45% 58.73% Alembic
APLLTD184.02B Healthcare Drug Manufacturers - Specialty & Generic -15.92% 45.65% Jubilant Pharmova
JUBLPHARMA174.95B Healthcare Drug Manufacturers - Specialty & Generic 27.78% 214.12% Natco Pharma
NATCOPHARM165.30B Healthcare Drug Manufacturers - Specialty & Generic -36.97% 40.23% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Suven Life Sciences Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Suven Life Sciences's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -84.60%, the Debt to Equity ratio from the most recent quarter is 0.00, and its Gross Profit Margin stands at 100.00%.
- What is the recent revenue and earnings growth for SUVEN?
- Looking at Suven Life Sciences's growth, its revenue over the trailing twelve months (TTM) was INR67M. Compared to the same quarter last year (YoY), quarterly revenue grew by -38.50%, and quarterly earnings saw a YoY growth of -38.50%.
- How much of SUVEN stock is held by insiders and institutions?
- Wondering who owns Suven Life Sciences stock? Company insiders (like executives and directors) hold about 67.50% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 3.88%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.